



Materials Inspection Record

1. Licensee Name: Munson Medical Center		2. Docket Number(s): 030-02074		3. License Number(s) 21-08317-01	
4. Report Number(s): 2021001			5. Date(s) of Inspection: March 22-24, 2021		
6. Inspector(s): Ryan Craffey		7. Program Code(s): 02240	8. Priority: 2	9. Inspection Guidance Used: 87131, 87132	
10. Licensee Contact Name(s): Dennis Aurand - RSO		11. Licensee E-mail Address: daurand@mhc.net		12. Licensee Telephone Number(s): 231-392-8612	
13. Inspection Type:		14. Locations Inspected:		15. Next Inspection Date (MM/DD/YYYY):	
<input type="checkbox"/> Initial <input checked="" type="checkbox"/> Routine <input checked="" type="checkbox"/> Announced <input type="checkbox"/> Non-Routine <input type="checkbox"/> Unannounced		<input checked="" type="checkbox"/> Main Office <input checked="" type="checkbox"/> Field Office <input type="checkbox"/> Temporary Job Site <input checked="" type="checkbox"/> Remote		03/22/2023 <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Extended <input type="checkbox"/> Reduced <input type="checkbox"/> No change	

16. Scope and Observations:

This was a routine inspection of a regional medical system authorized to use byproduct material for diagnostic and therapeutic medical purposes at its main facility in Traverse City, Michigan, and at five satellite facilities throughout northern Michigan. At the time of the inspection, the performed up to 20 diagnostic administrations of radiopharmaceuticals per day at the main hospital's nuclear medicine department, as well as occasional therapeutic administrations (around 50 each of I-131 and Ra-223 Xofigo since the last inspection) and Y-90 Therasphere administrations (13 since the last inspection). At the main hospital's cancer center, the licensee performed HDR remote afterloading brachytherapy using Ir-192, LDR permanent seed implants using I-125 and Pd-103, and IVB using Sr-90 (400+ fractions, 94 implants and 24 treatments since the last inspection, respectively). The licensee had not yet implanted any I-125 to localize non-palpable lesions. The licensee performed diagnostic administrations only at each of the five satellite facilities currently listed on its license. The RSO was based at the cancer center in Traverse City, assisted in his oversight of the various nuclear medicine departments by physics consultants who visited quarterly, and by an RSC which also met quarterly. In accordance with current agency policy during the Covid-19 PHE, this inspection was announced and conducted remotely by means of video teleconferencing. Relevant records were reviewed via secure file sharing and teleconference screen sharing.

Using the video teleconference platform, the licensee's staff provided tours of the nuclear medicine department, HDR suite, radiation oncology hot lab and waste storage area at the main facility in Traverse City, as well as the nuclear medicine departments at the satellite facilities in Grayling and Manistee. All areas were properly posted, and all licensed material adequately secured. The inspector observed the preparation and administration of diagnostic radiopharmaceuticals, as well as demonstrations of package receipt, instrument quality control checks, area surveys, waste handling, and use of Xe-133 and associated equipment for lung ventilation studies. The inspector also observed daily spot checks and source position checks of the HDR unit at the cancer center conducted prior to a treatment. Radiation instrumentation at each location was calibrated and operable, and staff utilized appropriate dosimetry and ALARA practices. The inspector discussed the conduct of Y-90 Theraspheres administrations and IVB treatments with authorized users, as well as HDR treatment planning and administration and receipt and handling of material for LDR permanent seed implants with authorized medical physicists. All staff were knowledgeable of radiation protection principles, licensee procedures, and regulatory requirements. The inspector also reviewed a selection of licensee records using a secure file sharing platform and teleconference screen sharing. These records included RSC meeting minutes, physics consultant audits, personnel dosimetry reports, written directives and treatment planning/verification documentation for all modalities, spot checks and full calibration reports for the HDR unit, and IVB sealed source leak testing results. No violations of NRC requirements were identified as a result of this inspection.